{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:11:57Z","timestamp":1772748717400,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":4393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1038\/modpathol.2010.165","type":"journal-article","created":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T05:24:25Z","timestamp":1301635465000},"page":"S44-S52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"S2","title":["Targeted therapies for thyroid tumors"],"prefix":"10.1016","volume":"24","author":[{"given":"Steven I","family":"Sherman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2010.165_bib1","first-page":"525","article-title":"International patterns and trends in thyroid cancer incidence, 1973\u20132002","volume":"20","author":"Kilfoy","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1038\/modpathol.2010.165_bib2","series-title":"SEER Cancer Statistics Review, 1975\u20132007","author":"Altekruse","year":"2010"},{"key":"10.1038\/modpathol.2010.165_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0","article-title":"Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973\u20131991","volume":"79","author":"Gilliland","year":"1997","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2010.165_bib4","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United States: burdens upon an aging, changing nation","volume":"27","author":"Smith","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2010.165_bib6","unstructured":"Radio-iodine halts one type of cancer. Life 1949;54\u201356."},{"key":"10.1038\/modpathol.2010.165_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.2164-0947.1949.tb00302.x","article-title":"The treatment of human thyroid disease with radioactive iodine","volume":"11","author":"Trunnell","year":"1949","journal-title":"Trans NY Acad Sci"},{"key":"10.1038\/modpathol.2010.165_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jcem-16-1-1","article-title":"An evaluation of various factors influencing the treatment of metastatic thyroid carcinoma with I 131","volume":"16","author":"Maloof","year":"1956","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/modpathol.2010.165_bib9","first-page":"12","article-title":"Lung metastases from differentiated thyroid carcinoma. A 40 years' experience","volume":"48","author":"Ronga","year":"2004","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1038\/modpathol.2010.165_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrc1836","article-title":"Pathogenetic mechanisms in thyroid follicular-cell neoplasia","volume":"6","author":"Kondo","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/modpathol.2010.165_bib11","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2010.165_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clon.2010.03.014","article-title":"Cytotoxic chemotherapy for differentiated thyroid carcinoma","volume":"22","author":"Sherman","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1038\/modpathol.2010.165_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2010.165_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1038\/modpathol.2010.165_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/joe.1.05895","article-title":"How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy","volume":"183","author":"Fagin","year":"2004","journal-title":"J Endocrinol"},{"key":"10.1038\/modpathol.2010.165_bib16","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/modpathol.2010.165_bib17","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2008-0607","article-title":"BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/modpathol.2010.165_bib18","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2008.20.1426","article-title":"BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer","volume":"27","author":"Xing","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/74651","article-title":"Mechanisms of angiogenesis and arteriogenesis","volume":"6","author":"Carmeliet","year":"2000","journal-title":"Nat Med"},{"key":"10.1038\/modpathol.2010.165_bib20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"10.1038\/modpathol.2010.165_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/jcem.86.2.7226","article-title":"Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma","volume":"86","author":"Klein","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/modpathol.2010.165_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/msy.2001.112592","article-title":"Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer","volume":"129","author":"Lennard","year":"2001","journal-title":"Surgery"},{"key":"10.1038\/modpathol.2010.165_bib23","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1210\/jc.2005-2836","article-title":"Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer","volume":"91","author":"Jo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/modpathol.2010.165_bib24","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.17.3682","article-title":"Refractory thyroid cancer: a paradigm shift in treatment is not far off","volume":"26","author":"Pfister","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ceb.2009.01.013","article-title":"Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets","volume":"21","author":"Knauf","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1038\/modpathol.2010.165_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2796.2009.02112.x","article-title":"Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma","volume":"266","author":"Santarpia","year":"2009","journal-title":"J Intern Med"},{"key":"10.1038\/modpathol.2010.165_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncponc1037","article-title":"Drug insight: gastrointestinal stromal tumors (GIST)\u2014the solid tumor model for cancer-specific treatment","volume":"5","author":"Sleijfer","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1038\/modpathol.2010.165_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1541-7786.MCR-07-2001","article-title":"BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells","volume":"6","author":"Sala","year":"2008","journal-title":"Mol Cancer Res"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib29","doi-asserted-by":"crossref","first-page":"9000","DOI":"10.1200\/jco.2009.27.15_suppl.9000","article-title":"Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer","volume":"27","author":"Flaherty","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/jc.2009-0373","article-title":"Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells","volume":"95","author":"Salerno","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib31","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/jco.2009.27.15_suppl.3513","article-title":"A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors","volume":"27","author":"Schwartz","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib32","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts","volume":"66","author":"Polverino","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2010.165_bib33","first-page":"920","article-title":"Anti-tumor activity of AMG 706, an oral multi-kinase inhibitor, in human medullary thyroid carcinoma xenografts","volume":"16","author":"Coxon","year":"2006","journal-title":"Thyroid"},{"key":"10.1038\/modpathol.2010.165_bib34","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","article-title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors","volume":"25","author":"Rosen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2010.165_bib36","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib (AMG 706) in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr Rev"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib38","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/jco.2010.28.15_suppl.3037","article-title":"Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer","volume":"28","author":"Bass","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib39","unstructured":"Sherman SI, Schlumberger MJ, Elisei R, et al. Exacerbation of postsurgical hypothyroidism during treatment of thyroid carcinoma with motesanib diphosphate (AMG 706). 89th Annual Meeting of The Endocrine Society: Toronto, ON, 2007."},{"key":"10.1038\/modpathol.2010.165_bib40","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2010.165_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2010.165_bib42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"10.1038\/modpathol.2010.165_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1038\/modpathol.2010.165_bib44","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib45","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","article-title":"Phase II trial of sorafenib in metastatic thyroid cancer","volume":"27","author":"Kloos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib46","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib47","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/jco.2009.27.15_suppl.6002","article-title":"Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients","volume":"27","author":"Brose","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib48","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1530\/EJE-09-0702","article-title":"Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma","volume":"161","author":"Hoftijzer","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1038\/modpathol.2010.165_bib49","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1210\/jc.2009-1923","article-title":"Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M.D. Anderson experience","volume":"95","author":"Cabanillas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib50","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1200\/jco.2010.28.15_suppl.5586","article-title":"Phase I trial of combination sorafenib and tipifarnib: the experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC)","volume":"28","author":"Cabanillas","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/CCO.0b013e32801173ea","article-title":"Medullary thyroid cancer: therapeutic targets and molecular markers","volume":"19","author":"Ball","year":"2007","journal-title":"Curr Opin Oncol"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib52","doi-asserted-by":"crossref","first-page":"14065","DOI":"10.1200\/jco.2007.25.18_suppl.14065","article-title":"Effect of sorafenib in symptomatic metastatic medullary thyroid cancer","volume":"25","author":"Kober","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib53","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1200\/JCO.2009.25.0068","article-title":"Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer","volume":"28","author":"Lam","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib54","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-05-2378","article-title":"BRAF is a therapeutic target in aggressive thyroid carcinoma","volume":"12","author":"Salvatore","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2010.165_bib55","doi-asserted-by":"crossref","unstructured":"Nagaiah G, Fu P, Wasman JK, et al. Phase II trial of sorafenib (BAY 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol 2009;27 (Suppl): abstract 6058.","DOI":"10.1200\/jco.2009.27.15_suppl.6058"},{"key":"10.1038\/modpathol.2010.165_bib56","unstructured":"Sherman SI . NCCN practice guidelines for thyroid cancer, version 2009a. 2009 [cited 1 June 2009]; available fromwww.nccn.org."},{"key":"10.1038\/modpathol.2010.165_bib57","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/thy.2008.0429","article-title":"The successful use of sorafenib to treat pediatric papillary thyroid carcinoma","volume":"19","author":"Waguespack","year":"2009","journal-title":"Thyroid"},{"key":"10.1038\/modpathol.2010.165_bib58","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":"An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases","volume":"91","author":"Kim","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/modpathol.2010.165_bib59","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7326\/0003-4819-148-7-200804010-00027","article-title":"Response to sunitinib in medullary thyroid cancer","volume":"148","author":"Kelleher","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1038\/modpathol.2010.165_bib60","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0b013e3282fc6cf7","article-title":"Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma","volume":"19","author":"Dawson","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1038\/modpathol.2010.165_bib61","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/jco.2008.26.15_suppl.6025","article-title":"Phase 2 study of sunitinib in refractory thyroid cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib62","doi-asserted-by":"crossref","unstructured":"Ravaud A, de la Fouchardi\u00e8re C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. 2008, [cited 15 December 2008]; available fromhttp:\/\/www.asco.org\/ASCO\/Abstracts+%26+Virtual+Meeting\/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33144.","DOI":"10.1200\/jco.2008.26.15_suppl.6058"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib63","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1200\/jco.2009.27.15_suppl.6056","article-title":"Phase II trial of continuous dosing of sunitinib in advanced, FDG-PET avid, medullary thyroid carcinoma (MTC) and well-differentiated thyroid cancer (WDTC)","volume":"27","author":"Carr","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/13543784.16.2.239","article-title":"Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis","volume":"16","author":"Herbst","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1038\/modpathol.2010.165_bib65","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2010.165_bib66","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2010.165_bib67","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"10.1038\/modpathol.2010.165_bib68","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","article-title":"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors","volume":"16","author":"Holden","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2010.165_bib69","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib70","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2010.165_bib71","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib72","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1200\/jco.2010.28.15_suppl.5503","article-title":"Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): a randomized, double-blind phase III trial (ZETA)","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib73","doi-asserted-by":"crossref","unstructured":"Fox E, Widemann BC, Whitcomb PO, et al. Phase I\/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma. J Clin Oncol 2009;27 (Suppl): abstract 10014.","DOI":"10.1200\/jco.2009.27.15_suppl.10014"},{"key":"10.1038\/modpathol.2010.165_bib74","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1210\/jc.2005-2472","article-title":"Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro","volume":"91","author":"Mitsiades","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/modpathol.2010.165_bib75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1038\/modpathol.2010.165_bib76","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib77","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2010.165_bib78","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","article-title":"Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies","volume":"64","author":"Bocci","year":"2004","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib79","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1200\/jco.2009.27.15_suppl.3521","article-title":"Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers","volume":"27","author":"Bible","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib80","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1517\/13543776.17.9.1035","article-title":"Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications","volume":"17","author":"Cui","year":"2007","journal-title":"Expert Opin Ther Pat"},{"key":"10.1038\/modpathol.2010.165_bib81","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1210\/en.2003-1762","article-title":"Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels","volume":"145","author":"Mineo","year":"2004","journal-title":"Endocrinology"},{"key":"10.1038\/modpathol.2010.165_bib82","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/01.pas.0000156103.37756.e2","article-title":"MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma","volume":"29","author":"Wasenius","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2010.165_bib83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/EP:11:1:19","article-title":"Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid","volume":"11","author":"Papotti","year":"2000","journal-title":"Endocr Pathol"},{"issue":"Suppl","key":"10.1038\/modpathol.2010.165_bib84","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/jco.2010.28.15_suppl.5502","article-title":"Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET","volume":"28","author":"Kurzrock","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1038\/modpathol.2010.165_bib85","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/modpathol.2010.165_bib86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2009.02.007","article-title":"Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited","volume":"15","author":"Loges","year":"2009","journal-title":"Cancer Cell"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2010165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2010165","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222031179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222031179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2010165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:07:27Z","timestamp":1760231247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222031179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":86,"alternative-id":["S0893395222031179"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2010.165","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapies for thyroid tumors","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2010.165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}